drugset / Trial / NCT00515021
Diurnal Variation of Plasminogen Activator Inhibitor-1
Phase 4
Completed
21 enrolled
Vanderbilt University Medical Center
National Center for Research Resources (NCRR) · collab
RandomizedCrossoverTriple-blindBasic science
Summary
To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning administration.
Timeline
- Start
- 2007-04
- Primary completion
- 2010-04
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eplerenone | Unknown | 100 mg | Oral |